Cargando…

Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells

Cisplatin (cis-diamminedichloroplatinum) is widely used for the treatment of solid malignancies; however, the development of chemoresistance hinders the success of this chemotherapeutic in the clinic. This study provides novel insights into the molecular and phenotypic changes in an isogenic oesopha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buckley, Amy M., Bibby, Becky AS., Dunne, Margaret R., Kennedy, Susan A., Davern, Maria B., Kennedy, Breandán N., Maher, Stephen G., O’Sullivan, Jacintha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469161/ https://www.ncbi.nlm.nih.gov/pubmed/30791601 http://dx.doi.org/10.3390/ph12010033

Ejemplares similares

Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma
por: Buckley, Amy M., et al.
Publicado: (2018)

Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib
por: Buckley, Amy M., et al.
Publicado: (2020)

Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma
por: Donlon, Noel E, et al.
Publicado: (2022)

The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling
por: Donlon, Noel E., et al.
Publicado: (2021)

1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours
por: Butler, Clare T., et al.
Publicado: (2019)

MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma
por: Bibby, Becky A. S., et al.
Publicado: (2015)

Altered Mitochondrial Function and Energy Metabolism Is Associated with a Radioresistant Phenotype in Oesophageal Adenocarcinoma
por: Lynam-Lennon, Niamh, et al.
Publicado: (2014)

The future of combination immunotherapy in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2023)

Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma
por: Melo, Ashanty M., et al.
Publicado: (2019)

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors
por: Kennedy, Susan A., et al.
Publicado: (2020)

Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma
por: Bibby, Becky A. S., et al.
Publicado: (2019)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses
por: Mylod, Eimear, et al.
Publicado: (2022)

Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma
por: Mongan, Ann Marie, et al.
Publicado: (2019)

Identification of TLR2 Signalling Mechanisms Which Contribute to Barrett’s and Oesophageal Adenocarcinoma Disease Progression
por: Flis, Ewelina, et al.
Publicado: (2021)

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer
por: Burke, Lorraine, et al.
Publicado: (2016)

Characterising the prognostic potential of HLA-DR during colorectal cancer development
por: Dunne, Margaret R., et al.
Publicado: (2020)

Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma
por: Doak, S H, et al.
Publicado: (2003)

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1
por: Garcia, Edwin, et al.
Publicado: (2016)

Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients
por: Davern, Maria, et al.
Publicado: (2022)

Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells
por: Davern, Maria, et al.
Publicado: (2021)

Energy Metabolism, Metabolite, and Inflammatory Profiles in Human Ex Vivo Adipose Tissue Are Influenced by Obesity Status, Metabolic Dysfunction, and Treatment Regimes in Patients with Oesophageal Adenocarcinoma
por: O’Connell, Fiona, et al.
Publicado: (2023)

Prognostic, Diagnostic and Predictive Biomarkers in the Barrett’s Oesophagus-Adenocarcinoma Disease Sequence
por: O’Dowd, Darragh, et al.
Publicado: (2022)

Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon.
por: Double, J. A., et al.
Publicado: (1983)

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1
por: Garcia, Edwin, et al.
Publicado: (2019)

Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma—An Emerging Role for Chemokines
por: Donlon, Noel E., et al.
Publicado: (2020)

Passive smoking and risk of oesophageal and gastric adenocarcinomas
por: Duan, L, et al.
Publicado: (2009)

Opposing Immune-Metabolic Signature in Visceral Versus Subcutaneous Adipose Tissue in Patients with Adenocarcinoma of the Oesophagus and the Oesophagogastric Junction
por: Heeran, Aisling B., et al.
Publicado: (2021)

Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?
por: Park, Jin-Soo, et al.
Publicado: (2021)

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)

HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients
por: Dunne, Margaret R., et al.
Publicado: (2017)

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
por: Alderson, Derek, et al.
Publicado: (2017)

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance
por: Kenicer, Juliet, et al.
Publicado: (2014)

Characterisation of a 4A QTL for Metribuzin Resistance in Wheat by Developing Near-Isogenic Lines
por: Bhattarai, Rudra, et al.
Publicado: (2021)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

Tonsillar metastasis of oesophageal adenocarcinoma
por: Struijs, Bram, et al.
Publicado: (2007)

Curcumin induces apoptosis-independent death in oesophageal cancer cells
por: O'Sullivan-Coyne, G, et al.
Publicado: (2009)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
por: Murphy, Adrian G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oq1mf40nnkgt2d7q5upccl1vs5